Search Results - inflammatory+bowel+disease+(ibd)

5 Results

Sort By:

Treatment of Irritable Bowel Syndrome with Molybdenum

Unmet NeedIrritable Bowel Syndrome is a chronic and incurable gastrointestinal disorder that affects 3-20% of Americans depending on certain sociocultural and comorbid factors. A poorly understood condition, current treatments consist of antispasmodics, antidiarrheals, and dietary restrictions. Unable to alleviate all its symptoms, researchers are in...

Published: 5/9/2024 | Inventor(s): Pankaj Pasricha, Lian Sheng Liu, Qian Li, Alfred Spormann

Keywords(s): Disease Indication, Gastrointestinal Disorders, Inflammatory Bowel Disease (IBD), Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Gastroenterology > Irritable Bowel Disease

MicroRNA Profiling Reveals Dynamic Changes in the Expression of miR-31 During IBD-associated Neoplastic Transformation

TITLE: Novel MicroRNA Diagnostic for IBD-associated Colorectal CancerCASE NUMBER: C10775 UNMET NEEDChronic idiopathic inflammatory bowel disease (IBD) predisposes to the development of colorectal carcinoma. Current preventive measures to diminish colorectal cancer mortality in IBD patients consist of periodic surveillance colonoscopies with...

Published: 5/9/2024 | Inventor(s): Stephen Meltzer, Alexandru Olaru

Keywords(s): Basic Research Biomarker, Biomarker, Cancers, Chronic Inflammatory Diseases, Cloning Reagents, Colorectal Cancer, Diagnostic Biomarker, Discovery/Research Tools, Disease Indication, Gastrointestinal Disorders, Inflammatory Bowel Disease, Inflammatory Bowel Disease (IBD), Mechanism-of-action Biomarker, Nucleotide, Research Reagent, Therapeutic Matter, Therapeutics

Inflammatory Bowel Disease (IBD): New Cytokine Biomarkers

C10931: Markers for Diagnosis and/or Prognosis of Irritable Bowel Disease and Syndrome Value Proposition: - The identified markers may be combined to optimize sensitivity and specificity. - These markers may be used in ELISA or Chip format. - Markers have been validated using colonic tissue biopsy samples. - Predicate technology and CPT codes already...

Published: 5/9/2024 | Inventor(s): Michael Centola, Nicholas Knowlton, Xuhang Li, Philip Alex

Keywords(s): Biomarker, Chronic Inflammatory Diseases, Clinical Diagnostics, Diagnostic Biomarker, Disease Indication, Gastrointestinal Disorders, In Vitro Diagnostics, Inflammatory Bowel Disease, Inflammatory Bowel Disease (IBD)

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology > Inflammatory Bowel Disease, Clinical and Disease Specializations > Inflammation > Chronic Inflammatory Diseases, Clinical and Disease Specializations > Rare Diseases, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Inflammation

Identification of Novel Serological Biomarkers for Inflammatory Bowel Disease Using E.coli Proteome Chip

C10584: Novel Diagnostics for IBDNovelty: This technology involves use of novel E. coli proteome chip to diagnose, monitor and select appropriate treatments for patients suffering from inflammatory bowel disease (IBD).Value Proposition: Current diagnostic methods for inflammatory bowel disease are invasive and patients find these tests unpleasant. The...

Published: 5/9/2024 | Inventor(s): Heng Zhu, Xuhang Li

PNU-120596 and 3-(2,4-dimethoxybenzylidene) Anabaseine (GTS-21) (both nAchRa7 agonists) and Methyllycaconitine (anAchRa7 antagonist), are Highly Effective Drugs in Therapy of Ulcerative Colitis (UC) and Crohn's Disease (CD)

C10382: Breakthrough Therapeutic for Inflammatory Bowel Diseases (IBD)Novelty: This technology identifies a nicotinic acetylcholine receptor isoform (nAChR7) that has a prevalent role in affecting Inflammatory Bowel Disease (IBD), as well as several agonist/antagonists to nAChR7, that are highly effective in both the prevention and therapy of ulcerative...

Published: 5/9/2024 | Inventor(s): Philip Alex, Michael Centola, Xuhang Li

Keywords(s): Chronic Inflammatory Diseases, Combination, Crohn's disease, Crohn's Disease, Disease Indication, Gastrointestinal Disorders, Inflammatory Bowel Disease, Inflammatory Bowel Disease (IBD), Natural compounds, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Targeted Therapy/Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Ulcerative Colitis, Ulcerative Colitis (UC)